A Phase 1, Open-Label, Randomized, Single-Dose, 5-Period Crossover Study to Determine the Bioavailability of Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Subjects
Latest Information Update: 25 Feb 2025
At a glance
- Drugs Vonoprazan (Primary)
- Indications Duodenal ulcer; Erosive oesophagitis; Gastric ulcer; Gastro-oesophageal reflux; Gastrointestinal disorders; Helicobacter infections; Peptic ulcer; Reflux oesophagitis
- Focus Pharmacokinetics
- Sponsors Phathom Pharmaceuticals
- 25 Feb 2025 New trial record